As of today (2026-07-09), Aligos Therapeutics's share price is €5.11. Aligos Therapeutics's GF Value is €2.11. Therefore, Aligos Therapeutics's Price-to-GF-Value for today is 2.42. Based on the relationship between the current stock price and the GF Value, GuruFocus believes Aligos Therapeutics is Significantly Overvalued.
The GF Value represents the intrinsic value of a stock, determined using GuruFocus' proprietary methodology. The GF Value Line on our stock Summary page provides an estimate of the stock’s fair-trading value.
To calculate this value, GuruFocus follows these steps:
We analyze historical correlations between the stock price and key business performance metrics, such as revenue, earnings, cash flow, and book value.
We identify the metrics that have the strongest historical correlation with the stock price and determine the historical multiples at which the stock has traded relative to these metrics.
Using these historical multiples as a reference, we estimate the stock's fair value while accounting for future business growth. Adjustments may be made based on the company’s past returns and growth trends.
GuruFocus believes that the GF Value Line represents the fair value at which a stock should trade. Stock prices typically fluctuate around this line. If a stock’s price is significantly above the GF Value Line, it is considered overvalued, and its future returns are likely to be lower. Conversely, if the stock price is significantly below the GF Value Line, its future returns are likely to be higher.
Aligos Therapeutics (STU:5WK0) GF Value Explanation
Based on the relationship between the current stock price and the GF Value, GuruFocus provides the following 6 ratings:
(1) These are some simple examples. You can access our GF Valuation filter under All-in-One Screener’s Fundamental tab, and Price-to-GF-Value filter under Valuation Ratio tab and set your own criteria.
(2) A sufficient margin of safety exists only when the stock is undervalued.
Possible Value Trap, Think Twice companies are those that appear significantly undervalued based on their Price-to-GF-Value ratio, but whose fundamentals show signs of weakness.
Indicators that a company may be a value trap include:
* Deteriorating Financial Health: A low Altman Z-scores indicates a higher risk of bankruptcy, or a low Piotroski F-Score. * Earnings Manipulation: A high Beneish M-score indicates potential earnings manipulation, raising concerns about the reliability of reported financials. * Stagnant or Declining Growth: Lack of revenue or earnings growth, or a recent slowdown, may signal limited future prospects.
Investors should conduct thorough due diligence, examining financial statements and growth indicators, to avoid falling into value traps.
Aligos Therapeutics's Price-to-GF-Value for today is calculated as
Price-to-GF-Value
=
Share Price
/
GF Value
=
5.11
/
2.11
=
2.42
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aligos Therapeutics (STU:5WK0) has a GF Value of €2.11 as of Jul. 09, 2026. GF Value represents the current intrinsic value of a stock derived from our exclusive method. View historical data on Aligos Therapeutics and its competitors.
Is Aligos Therapeutics' GF Value too high?
Aligos Therapeutics' current GF Value is €2.11. Overall, Aligos Therapeutics has a GF Score™ of 25/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Aligos Therapeutics' GF Value compare to SNTI and NTRB?
Aligos Therapeutics' GF Value of €2.11 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Value for a Biotechnology company?
A good GF Value depends on the Biotechnology industry context. However, GF Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Value mean?
A high GF Value can signal that a stock is expensive relative to its fundamentals. GF Value represents the current intrinsic value of a stock derived from our exclusive method. View historical data on Aligos Therapeutics and its competitors. Aligos Therapeutics's current GF Value is €2.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aligos Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Aligos Therapeutics (STU:5WK0) is currently considered Significantly Overvalued. The stock's GF Value™ is €2.11, compared to a current price of €5.11 — trading 142.2% above its estimated fair value. The current GF Value is €2.11. Aligos Therapeutics' overall GF Score™ is 25/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Value calculated?
GF Value is calculated from a company's financial statements. For Aligos Therapeutics (STU:5WK0), the current GF Value is €2.11 as of Jul. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Aligos Therapeutics (STU:5WK0) Overvalued in 2026?
Based on GuruFocus' analysis, Aligos Therapeutics stock appears to be overvalued.
The current stock price of €5.11 is trading 142.2% above its estimated GF Value™ of €2.11.
GuruFocus considers Aligos Therapeutics to be Significantly Overvalued.
Key valuation signals for STU:5WK0:
GF Value: €2.11
GF Value™: €2.11 vs. price of €5.11 (142.2% above fair value)
No single metric tells the full story. See the STU:5WK0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Aligos Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics for liver diseases and viral infections. Its pipeline includes drug candidates targeting chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), obesity, and coronavirus infections, with programs such as pefivfoscorvir sodium for HBV, ALG-055009 for MASH and obesity, and ALG-097558 for coronavirus infections.
25GF Score
Get the complete analysis for STU:5WK0
GF Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:5WK0 has been successfully added to your 